DXCM Dexcom Earnings and EPS analysis

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 95

EPS in 2026 (TTM): $2.59

Last Report Period Date: Sep 30, 2026

Currently, DXCM's trailing twelve months (TTM) EPS stands at $2.59, according to the most recent financial reports. Dexcom's earnings per share in 2025 came in at $2.14, marking an increase from $1.46 in 2024. DXCM recorded an EPS of $0.73 for the quarterly period ending on Sep 30, 2026.

DXCM earnings history

Historical annual and quarterly earnings per share (EPS) data for Dexcom
EPS (TTM)
$2.59
EPS Growth YoY (Quarterly)
0%
EPS (Quarterly)
$0.73
EPS Growth (Quarterly)
12.3%

In 2025, Dexcom's EPS was $2.14, an increase of 46.6% from $1.46 in 2024. For the quarter ending Sep 30, 2026, the EPS was $0.73, reflecting no change compared to the same quarter last year. DXCM's TTM EPS is $2.59 as of September 2026. Dexcom's EPS for 2024 was $1.46, a 4.3% rise from 2023.

DXCM EPS vs price chart

DXCM EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
0%
EPS growth YoY
46.6%
EPS growth 3Y avg
34.5%
EPS growth 5Y avg
7.9%

Dexcom has recorded no change in earnings per share over the past 12 months (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS annual growth rate of 34.5% per year for the last 3 years. Over the last five years, the company had an average annual EPS growth of 7.9%.

DXCM Earnings Waterfall

Breakdown of revenue, profit and net income for Dexcom

DXCM Earnings vs Peers

What are the earnings of DXCM compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
MDT Medtronic Plc 24.69 3.3% 9.8% 6.9%
DXCM Dexcom Inc 31.43 46.6% 34.5% 7.9%
ABT Abbott Laboratories 39.88 -51.4% -1.8% 8.2%
JNJ Johnson & Johnson 42.45 90.6% 17.7% 14.8%
WST West Pharmaceutical Services Inc 45.88 1.2% -4.6% 7.9%
EW Edwards Lifesciences Corp 59.77 -73.6% -9.2% 6.9%
BDX Becton Dickinson & Company 64.98 -0.9% -0.6% 16.2%
TNDM Tandem Diabetes Care Inc N/A -106.8% N/A N/A
QDEL QuidelOrtho Corporation N/A 45.4% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.